Abstracts tagged "prevention"

Abstract Number: 0938 • ACR Convergence 2023
Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum
Sunhwa Kim¹, Thierry Sornasse², Vishal Kakkar³, Rebecca Ross⁴, Yingtao Bi⁵, Hengcheng Hu², Lisa Hazelwood², Lauren Reinke-Breen⁶, jozsef karman⁷, Chris Butler², Jennifer Van Camp² and Francesco Del Galdo⁸, ¹AbbVie, Inc., South San Francisco, CA, ²AbbVie, Inc., North Chicago, IL, ³University of Leeds, Leeds, United Kingdom, ⁴Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁵AbbVie, Inc., Worcester, MA, ⁶AbbVie, Inc., Vernon Hills, IL, ⁷AbbVie, Inc., San Francisco, CA, ⁸University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease that affects multiple organs asynchronously, leading to highly variable fibrotic damage and consequent increased morbidity and mortality.…
Abstract Number: 2283 • ACR Convergence 2023
Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness
Arthur Mageau¹, Julia Simard², Elisabet Svenungsson³ and Elizabeth Arkema⁴, ¹Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden / Internal Medicine Unit, Hopital Bichat, Paris, France, ²Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ³Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Real-world data assessing the effectiveness of the anti-SARS-CoV2 vaccination in patients living with systemic lupus erythematosus (SLE) are currently lacking. We aimed to describe…
Abstract Number: 1087 • ACR Convergence 2023
Characterizing Herpes Zoster Vaccination Patterns in Rheumatoid Arthritis Patients in a Tertiary Care Clinic: A Quality Improvement Approach
Sara Faghihi-Kashani, Arooj Babar and Janice Lin, Stanford University, Palo Alto, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) face an increased risk of herpes zoster (HZ) infection, notably those on immunosuppressive therapy. Herpes zoster infection is associated…
Abstract Number: 2285 • ACR Convergence 2023
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) – Study Update
J. Patricia Dhar¹, Hannah Forsythe², Louis Saravolatz¹ and Susanna Szpunar³, ¹Ascension St. John Hospital and Wayne State University School of Medicine, Detroit, MI, ²Michigan Department of Human and Health Services, Lansing, MI, ³Ascension St. John Hospital, Detroit, MI
Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to…
Abstract Number: 1089 • ACR Convergence 2023
Improving Recombinant Zoster Vaccination Rates Among Immunosuppressed Veterans in an Academic Rheumatology Clinic
Nagendra Pokala¹, Benjamin Gardner², Avni Amratia¹, Daniel Emesiani³, Jiby Mathew⁴, Rashmi Arora⁵, Una Makris⁶ and Swathi Reddy⁷, ¹Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, ³Baylor Scott and White Medical Center McKinney, Dallas, TX, ⁴VA North Texas Healthcare System, Dallas, TX, ⁵Department of Internal Medicine, UT Southwestern Medical Center; VA North Texas Healthcare System, Dallas, TX, ⁶UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁷UT Southwestern Medical Center / Dallas VA Medical Center, Colleyville, TX
Background/Purpose: Due in part to immunosuppressant medications, patients with rheumatic diseases not only carry a higher risk of herpes zoster reactivation but also worse outcomes.…
Abstract Number: 2490 • ACR Convergence 2023
Safety and Efficacy of Mycophenolate Mofetil in New-onset Systemic Lupus Erythematosus with High Titer of Anti-dsDNA Antibody and Without Major Organ Involvement: A Multicenter Randomized Controlled Trial
Junna Ye¹, Yijun You², Zhuochao Zhou², Jingyi Wu², Fan wang² and Chengde Yang², ¹Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Previous clinical trials of mycophenolate mofetil (MMF) in SLE were mainly focused on lupus nephritis (LN) (patients have been diagnosed with LN). In the…
Abstract Number: 0133 • ACR Convergence 2023
COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Systemic Lupus Erythematosus: Results from the COVAD Study
Madiha Fathima¹, Bohdana Doskaliuk², Julius Lindblom¹, Elena Nikiphorou³, Chris Wincup⁴, Sreoshy Saha⁵, Syahrul Sazliyana Shaharir⁶, Wanruchada Katchamart⁷, Phonpen Akarawatcharangura Goo⁸, Lisa Traboco⁹, Yi-Ming Chen¹⁰, Kshitij Jagtap¹¹, James Lilleker¹², Arvind Nune¹³, John Pauling¹⁴, Vishwesh Agarwal¹⁵, Dey Dzifa¹⁶, CARLOS ENRIQUE TORO GUTIERREZ¹⁷, CARLO VINICIO CABALLERO¹⁸, Hector Chinoy¹⁹, Rohit Aggarwal²⁰, Vikas Agarwal²¹, Latika Gupta²² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²SHEI "Ivano-Frankivsk national medical university", Ivano-Frankivsk, Ukraine, ³King's College London, London, United Kingdom, ⁴King's College Hospital, London, United Kingdom, ⁵Mymensingh Medical College, Faridpur, Bangladesh, ⁶Faculty of Medicine, Universiti Kebangsaan Malaysia, 56000, Cheras, Kuala Lumpur, Malaysia, ⁷Mahidol University, Bangkok, Thailand, ⁸Department of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand, ⁹University of the Philippines - Manila, St Luke's Medical Center - Bonifacio Global City, Paranaque, Manila, Philippines, ¹⁰Taichung Veterans General Hospital, Taichung, Taiwan, ¹¹Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ¹²Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK; Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK. Orcid ID: 0000-0002-9230-4137., Manchester, United Kingdom, ¹³Southport & Ormskirk NHS Foundation Trust, Liverpool, United Kingdom, ¹⁴North Bristol NHS Trust, Bristol, United Kingdom, ¹⁵Mahatma Gandhi Missions Medical College, Lucknow, India, ¹⁶Department of Medicine and Therapeutics, University of Ghana School of Medicine and Dentistry, College of Health Sciences, Korle-Bu, Accra, Ghana, ¹⁷Centro de Estudios de Reumatología y Dermatología SAS, Cali, Colombia, ¹⁸REUMACARIBE IPS, Barranquilla, Colombia, ¹⁹The University of Manchester, Sale, United Kingdom, ²⁰University of Pittsburgh, Pittsburgh, PA, ²¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²²Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: COVID-19 vaccines have been proven to be safe in healthy populations. However, data on delayed adverse effects (AEs) in people with autoimmune diseases (AIDs),…
Abstract Number: 1097 • ACR Convergence 2023
Improving Vaccine Uptake of the Pneumococcal 20-valent Conjugate Vaccine (PCV20) in Young Rheumatic Disease Patients Using a Brief Intense Partnership Program
Kelsey Pasch¹, Stephen Lindsey² and Takeda Ferguson³, ¹Louisiana State University -- New Orleans, Baton Rouge, LA, ²LSU Health Science Center, New Orleans, LA, ³LSU Health Science Center School of Public Health, New Orleans, LA
Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) are at increased risk of infection. The Centers for Disease Control and Prevention (CDC) and the ACR strongly…
Abstract Number: 2558 • ACR Convergence 2023
Aortic Aneurysms in a Multicenter Cohort of 196 Patients with Aortitis Related to Giant Cell Arteritis Treated with Tocilizumab
Fernando López¹, Javier Loricera², Adrián Martín-Gutiérrez³, Carmen Secada³, Santos Castañeda⁴, Clara Moriano Morales⁵, Javier Narvaez⁶, Vicente Aldasoro⁷, Olga Maiz⁸, Rafael Benito Melero-Gonzalez⁹, PALOMA VELA¹⁰, Susana Romero Yuste¹¹, Eugenio De Miguel¹², Eva Galindez-Agirregoikoa¹³, Jesús Carlos Fernández López¹⁴, Ivan Ferraz Amaro¹⁵, Julio Sánchez-Martín³, Jose L. Callejas¹⁶, Patricia Moya Albarado¹⁷ and Ricardo Blanco¹⁸, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de León, León, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital Universitario de Navarra, Pamplona, Spain, ⁸Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ⁹CHU Vigo, O Carballino, Spain, ¹⁰Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Basurto University Hospital, Bilbao, Spain, ¹⁴Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁶Unit of Systemic Autoimmune Diseases, Hospital San Cecilio, Granada, Spain, ¹⁷Hospital Universitario de Sant Pau, Barcelona, Spain, ¹⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Aortic aneurysms is a serious complication that can occur in patients with giant cell arteritis (GCA) (1-2). Tocilizumab (TCZ) is approved for GCA. Nevertheless,…
Abstract Number: 0198 • ACR Convergence 2023
Improving Vaccination Uptake of Herpes Zoster in Young Rheumatic Disease Patients Ages 18-49 Using Specialty Pharmacy Partnership
Stephen Lindsey¹, Brittany Hill², Sheela Sheth³ and Arya Loghmani², ¹LSU Health Science Center, New Orleans, LA, ²Louisiana State University, New Orleans, LA, ³Tulane University, New Orleans, LA
Background/Purpose: Herpes zoster (HZ), also known as shingles, causes an estimated one million cases annually in the United States. Many studies have shown that the…
Abstract Number: 1099 • ACR Convergence 2023
Improving Hydroxychloroquine Dosing and Eye Screening Compliance in Patients with Connective Tissue Disorder
Maria Salgado Guerrero¹ and Angelo Gaffo², ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL; Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases. To minimize the risk of retinal toxicity, the American College…
Abstract Number: 2581 • ACR Convergence 2023
Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies
Samir Rachid Zaim¹, Adam Savage¹, Mark Gillespie¹, Christy Bennett¹, lynne Becker¹, LauraKay Moss², Marie Feser², Jess Edison³, Ted R Mikuls⁴, Michael Holer², kevin Deane² and Xiao-Jun Li¹, ¹Allen Institute for Immunology, Seattle, WA, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³Walter Reed Military Medical Center, Bethesda, MD, ⁴Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) includes a stage of development that can be termed 'pre-RA' and defined as the presence of abnormal biomarkers and/or other features…
Abstract Number: 0203 • ACR Convergence 2023
Projecting the Impact on Clinical Outcomes in ANCA-Associated Vasculitis of Delaying Retreatment with Rituximab for Vaccine Optimization
Zachary Wallace¹, Aaron Wu², Shruthi Srivatsan², Naomi Patel², Jeffrey Sparks³, Eli Miloslavsky², Hyon K. Choi⁴, Peter Merkel⁵, John Stone⁶ and Emily Hyle², ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: Rituximab (RTX) is effective for maintaining remission in ANCA-associated vasculitis (AAV) but increases risks for vaccine-preventable severe infections and reduces the immune response to…
Abstract Number: 1351 • ACR Convergence 2023
HPV Vaccination in Adolescent and Young Adult Patients Seen in an Academic Rheumatology Center
Caroline Siegel¹, Lauren Robinson¹, Deanna Jannat-Khah¹, Avi Mikhaylov¹, Nancy Pan¹ and Lisa Sammaritano², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Adolescent and young adults (AYAs) with rheumatic disease (RD) may face disproportionate risk of HPV and associated cancers due to immune dysregulation, immunosuppression and…
Abstract Number: 2584 • ACR Convergence 2023
Gut Microbiome and Intestinal Inflammation in Preclinical Stages of Rheumatoid Arthritis
Benoît Thomas P. GILBERT¹, Raul Yhossef TITO TADEO², Céline LAMACCHIA¹, Olivia STUDER¹, Delphine COURVOISIER¹, Jeroen RAES³ and Axel Finckh⁴, ¹Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium, ³Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven., Leuven, Belgium, ⁴HUG, Geneva, Switzerland
Background/Purpose: We attempted to replicate and expand previous findings of an increased abundance of Prevotellaceae in early untreated Rheumatoid Arthritis (RA) or its preclinical stages,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.